2025-08-29

Q2 2025 Results

Rev $177.4B (+4.8% YoY), EPS $0.88 (+57% YoY)

2025-06-06

Q1 2025 Results

Rev $165.6B (+2.5% YoY), EPS $0.56 (-11.1% YoY)

2024-12-06

Q3 2024 Results

Financial data not available in provided content

2024-08-30

Q2 2024 Results

Rev $169.3B (+4.8% YoY), EPS $0.56 (-42.9% YoY)

2024-06-07

Q1 2024 Results

Rev $161.5B (+6.0% YoY), EPS $0.63 (+200% YoY)

2025-03-14

FY2025 2025 Results

📌 Filing date of March 14, 2025 for fiscal year ending January 31, 2025

2025-11-20

Q3 Earnings + NYSE to Nasdaq Transfer

Q3 2025 results disclosed, stock/debt moving NYSE to Nasdaq Dec 9

2025-11-14

CEO Transition

McMillon retiring Jan 31, 2026; Furner appointed new CEO

2025-10-22

Controller Appointed

Dwayne Milum appointed SVP & Controller, $600K salary

2025-09-22

Executive 10b5-1 Trading Plan

Chief People Officer plans to sell max 148,665 shares starting Jan 2026

2025-09-19

Executive 10b5-1 Trading Plan

Daniel Danker to sell max 109,976 shares via automated plan

2025-09-05

CFO 10b5-1 Trading Plan

CFO Rainey to sell 40,000 shares in Feb-Mar 2026

2025-08-21

Q2 Earnings

Results for three and six months ended July 31, 2025

2025-06-06

Annual Shareholder Meeting

91.36% turnout, all 12 directors elected, 7 shareholder proposals rejected

2025-05-15

Q1 Earnings + HQ Relocation

Q1 2025 results for quarter ended April 30, HQ moved to 1 Customer Drive

2025-04-28

Debt Offering

$4B notes issued: Floating rate 2027, 4.1% 2027, 4.35% 2030, 4.9% 2035

2025-04-09

Investment Community Meetings

Press release issued for investor meetings

2025-03-17

John Furner 10b5-1 Trading Plan

157,500 shares max sale over 12 months

2025-03-17

CEO 10b5-1 Trading Plan

McMillon to sell 233,000 shares Jun 2025-May 2026

2025-02-20

Q4 FY2025 Earnings

Results for Q4 and fiscal year ended January 31, 2025

2024-11-22

Executive 10b5-1 Trading Plan

Kathryn McLay to sell 40,000 shares over 10 months

2024-11-19

Q3 Earnings

Results for three and nine months ended October 31, 2024

2024-10-18

Opioid Derivative Lawsuit Settlement

$123M insurance payout to settle opioid-related shareholder derivative claims

2024-09-06

CFO 10b5-1 Trading Plan

CFO Rainey to sell max 95,800 shares through Dec 2025

2024-08-15

Director Appointed

Robert E. Moritz Jr. appointed to Board

2024-08-15

Q2 2024 Earnings

Results for three and six months ended July 31, 2024

2024-06-07

Annual Shareholder Meeting

91% attendance, all 11 directors elected, executive comp approved

2024-05-16

Q1 2024 Earnings

Results for three months ended April 30, 2024